Company Description
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally.
The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.
It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies.
In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development.
Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG.
It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies.
The company was founded in 1909 and is headquartered in Barcelona, Spain.
| Country | Spain |
| Founded | 1940 |
| IPO Date | May 17, 2006 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 26,314 |
| CEO | Nacho Abia |
Contact Details
Address: 1585 Broadway, Suite 2376 New York, New York 10036 United States | |
| Phone | 212-969-3335 |
| Website | grifols.com |
Stock Details
| Ticker Symbol | GRFS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001438569 |
| CUSIP Number | 398438408 |
| ISIN Number | US3984384087 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Thomas H. Glanzmann | Executive Chairman |
| Nacho Abia | Chief Executive Officer and Director |
| Alfredo Arroyo Guerra | Chief Financial Officer and Vice President |
| Mrs. Eva Bastida Tubau | Corporate Vice President and Director of Scientific and Medical Affairs |
| Nuria Pascual Lapeña | Vice President of Corporate Treasury, Risk Management Investor Relation and Sustainability Officer |
| David Ian Bell | Chief Corporate Development, Legal and Data Protection Officer |
| Maria Teresa-Rioné Llano | Chief Communications Officer |
| Montserrat Gaja Llamas | Chief Human Resources Officer |
| Vicente Blanquer Torre | Chief Quality Officer |
| Alberto Grifols Roura | President of the Bio Supplies Division |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2024 | 6-K | Report of foreign issuer |
| Apr 10, 2024 | 6-K | Report of foreign issuer |
| Apr 5, 2024 | 6-K | Report of foreign issuer |
| Apr 4, 2024 | 6-K | Report of foreign issuer |
| Apr 2, 2024 | 6-K | Report of foreign issuer |
| Mar 22, 2024 | 6-K | Report of foreign issuer |
| Mar 14, 2024 | 6-K | Report of foreign issuer |
| Mar 8, 2024 | 6-K | Report of foreign issuer |
| Mar 8, 2024 | 6-K | Report of foreign issuer |
| Mar 1, 2024 | 6-K | Report of foreign issuer |